Bisphosphonate-associated osteonecrosis of the jaw in Ontario: A survey of oral and maxillofacial surgeons

Journal of Rheumatology

Volumn 38, Issue 7, 2011, Pages 1396-1402

  Khan, Aliya A ^a   Rios, Lorena P ^a   Sándor, George K B ^b   Khan, Nazir ^a   Peters, Edmund ^c   Rahman, Mohammed O ^a   Clokie, Cameron M L ^b   Dore, Edward ^a   Dubois, Sacha ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d ST JOSEPH'S CARE GROUP   (Canada)

Author keywords

Bisphosphonate; Jaw; Ontario; Osteonecrosis; Osteoporosis; Survey

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CANCER PATIENT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; HEALTH SURVEY; HUMAN; INCIDENCE; JAW OSTEONECROSIS; LOW DRUG DOSE; MALE; METABOLIC BONE DISEASE; OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SURGEON; TELEPHONE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DISEASES, METABOLIC; CHILD; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEALTH SURVEYS; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASMS; ONTARIO; OSTEOPOROSIS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RISK FACTORS; SURGERY, ORAL; YOUNG ADULT;

EID: 79960026942     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100221     Document Type: Article

References (25)

1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. (Pubitemid 37064711)
2. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34. (Pubitemid 38542516)
3. Khan AA, Sandor GK, Dore E, Morrison AD, Alsahli M, Amin F, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009;36:478-90.
4. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91. (Pubitemid 351229318)
5. Khan AA, Sandor GK, Dore E, Morrison AD, Alsahli M, Amin F, et al. Canadian Consensus Practice Guidelines for Bisphosphonate Associated Osteonecrosis of the Jaw. J Rheumatol 2008;35:1391-7. (Pubitemid 352000790)
6. Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: A population-based analysis. J Natl Cancer Inst 2007;99:1016-24. (Pubitemid 47240676)
7. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008;44:857-69.
8. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61. (Pubitemid 46780635)
9. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826-36. (Pubitemid 351768801)
10. Abu-Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J, Acil Y, et al. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Cranio-Maxillofac Surg 2008;36:95-103.
11. Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: An institutional inquiry. J Am Dent Assoc 2009;140:61-6.
12. Hong JW, Nam W, Cha IH, Chung SW, Choi HS, Kim KM, et al. Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia. Osteoporosis Int 2010;21:847-53.
13. Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 2009;115:1631-7.
14. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007;65:1328-31. (Pubitemid 46915477)
15. Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007;18:2015-9. (Pubitemid 350286242)
16. Tosi P, Zamagni E, Cangini D. Bisphosphonates and osteonecrosis of the jaw: Incidence in a homogenous series of patients with newly diagnosed multiple myeloma treated with zoledronic acid. Blood 2005;106:3467a.
17. Cafro AM, Barbarano LA, Andriani A. Osteonecrosis of the jaw associated with chronic bisphosphonates therapy: An Italian experience [abstract 5152]. American Society of Hematology Annual Meeting, 2005.
18. Pozzi S, Marcheselli R, Sacchi S. Analysis of frequency and risk factors for developing bisphosphonate associated necrosis of the jaw [abstract 5057]. American Society of Hematology Annual Meeting, 2005.
19. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaws and bisphosphonates. N Engl J Med 2005;353:99-102.
20. Cartsos V, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: A medical claims study of 714,217 people. J Am Dent Assoc 2008;139:23-30.
21. Bamias A, Dimopoulos MA. Thalidomide and immunomodulatory drugs in the treatment of cancer. Expert Opin Invest Drugs 2005;14:45-55.
22. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91:968-71. (Pubitemid 44023154)
23. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-23. (Pubitemid 46343586)
24. Felsenberg D, Hoffmeister B, Amling M. Bisphosphonattherapie assoziierte. Kiefernekrosen Deutsches Arzteblatt 2006;46: A3078-80.
25. Brogan Inc. National private plan data; August 12th 2009.